Advanced drug delivery systems market seen reaching $433.56B by 2030

The advanced drug delivery systems market is projected to grow from $310.15 billion in 2026 to $433.56 billion by 2030, according to The Business Research Company. Demand for personalized medicine, biologics and nanotechnology-based therapies is expected to keep pushing the market at an 8.7% CAGR.

Why it matters: - Advanced drug delivery systems are becoming a bigger part of pharmaceutical development because they can improve therapeutic outcomes while reducing side effects. - The market is expanding as chronic disease burdens rise and drugmakers look for more precise, patient-friendly ways to deliver treatments. - The market is projected to reach $433.56 billion by 2030, which signals sustained investment in delivery technologies across pharma and biotech.

What happened: - The Business Research Company released its "Advanced Drug Delivery Systems Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035" on July 23, 2026. - The report says the market will grow from $285.59 billion in 2025 to $310.15 billion in 2026. - The report projects an 8.7% CAGR through the forecast period, with the market reaching $433.56 billion by 2030. - The report includes a free sample and the full market report.

The details: - Historical growth was driven by pharmaceutical R&D expansion, more chronic disease cases, progress in formulation science, higher use of injectable drug treatments and a stronger focus on treatment outcomes. - Future growth is expected to come from personalized medicine, broader use of biologic drugs, nanotechnology-based therapies, efforts to reduce drug-related side effects and investment in advanced delivery platforms. - The report points to targeted delivery methods, nanocarrier formulations, controlled-release systems, biologic and biosimilar therapies, and patient-friendly drug administration as major trends. - Advanced drug delivery systems are designed to deliver drugs at optimal dosages, target specific tissues and release medications at controlled rates. - The technology is intended to improve bioavailability and help medicines act where they are most needed. - Chronic disease prevalence is a key growth driver, including conditions linked to tobacco use, poor diet, physical inactivity and excessive alcohol consumption. - The United Nations reported in May 2023 that chronic diseases account for seven out of 10 deaths in the United States and more than 1.7 million deaths a year.

Between the lines: - The report's forecast suggests drug delivery is shifting from a supporting function to a competitive advantage in treatment design. - Strong demand for biologics and personalized medicine points to more complex therapies that need more sophisticated delivery systems. - North America’s current lead and Asia-Pacific’s faster growth outlook suggest mature markets will keep driving revenue while emerging markets add speed.

What's next: - The market report says new enhancements include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated technology and trend analysis. - North America is expected to remain a major market, while Asia-Pacific is projected to be the fastest-growing region through the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa for a global regional outlook. - The Business Research Company lists contact details for expert inquiries and follow-up on the report.